1. Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic Acid 
Fred Saad, Scott Segal, James Eastham 
European Urology 
Volume 65, Issue 1, Pages (January 2014)
DOI: /j.eururo
Copyright © 2012 European Association of Urology Terms and Conditions

2. Fig. 1
Trial registration and Consolidated Standards of Reporting Trials (CONSORT) information. The phase 3 trial has no trial registry name, number, or URL. Patient enrollment and study treatment took place between June 1998 and January Results for the phase 3 trial were published in 2002 [11] and 2004 [10]. The CONSORT diagram was originally published in 2004 [10].
* Three patients, one randomly assigned to receive zoledronic acid 4mg and two randomly assigned to receive zoledronic acid at 8/4mg, never received the study drug and were not included in the safety analysis. One patient randomly assigned to receive zoledronic acid at 8/4mg incorrectly received 4mg; this patient was included in the 8/4-mg group for efficacy and in the 4-mg group for safety analysis.
European Urology  , DOI: ( /j.eururo )
Copyright © 2012 European Association of Urology Terms and Conditions

3. Fig. 2
Kaplan-Meier estimates for overall survival by baseline prostate-specific antigen (PSA) in (A) the placebo group and (B) the zoledronic acid group. Median PSA level (77.3 ng/ml) was used as the high/low cut-off point.
CI=confidence interval; RR=relative risk.
European Urology  , DOI: ( /j.eururo )
Copyright © 2012 European Association of Urology Terms and Conditions

4. Fig. 3
Cumulative incidence functions for bone disease progression (BDP) by baseline prostate-specific antigen (PSA) in (A) the placebo group and (B) the zoledronic acid group. Median PSA level (77.3 ng/ml) was used as the high/low cut-off point.
CI=confidence interval; RR=relative risk.
European Urology  , DOI: ( /j.eururo )
Copyright © 2012 European Association of Urology Terms and Conditions

5. Fig. 4
Cumulative incidence functions for skeletal-related events (SREs) by baseline prostate-specific antigen (PSA) in (A) the placebo group and (B) the zoledronic acid group. Median PSA level (77.3 ng/ml) was used as the high/low cut-off point.
CI=confidence interval; RR=relative risk.
European Urology  , DOI: ( /j.eururo )
Copyright © 2012 European Association of Urology Terms and Conditions

6. Fig. 5
Change in prostate-specific antigen (PSA) levels versus baseline.
ZOL=zoledronic acid.
European Urology  , DOI: ( /j.eururo )
Copyright © 2012 European Association of Urology Terms and Conditions

7. Fig. 6
Forest plot of relative risks for survival, bone disease progression (BDP), and first skeletal-related event (SRE) in correlative analyses between time-dependent prostate-specific antigen (PSA) levels and clinical outcomes.
ZOL=zoledronic acid.
European Urology  , DOI: ( /j.eururo )
Copyright © 2012 European Association of Urology Terms and Conditions